ESMO20: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer

Stephen Johnston | ESMO 2020 | Onkologi /hematologi | September 24, 2020

Speaker: Stephen Johnston

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. In this MEDtalk Professor Stephen Johnston, from the Royal Marsden Hospital NHS Foundation Trust, London, presents the new data presented at ESMO 2020.

Professor Stephen Johnston, The Royal Marsden Hospital NHS Foundation Trust, London